Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and monodansylcadaverine

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with monodansylcadaverine in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(monodansylcadaverine)		Trials
(monodansylcadaverine)		Recent Studies (post-2010) (monodansylcadaverine)
9,156187552402060

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Garcia Gil, M; Sanchez Crespo, M1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and monodansylcadaverine

ArticleYear
Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes.
    Immunopharmacology, 1983, Volume: 6, Issue:4

    Topics: Adamantane; Amantadine; Antineoplastic Agents; Cadaverine; Diamines; Humans; Neutrophils; Phagocytosis; Phosphatidylcholines; Platelet Activating Factor; Rimantadine

1983